2023
Tobacco use and cancer‐related symptom burden: Analysis of the US Population Assessment of Tobacco and Health Study
Price S, Palmer A, Fucito L, Graboyes E, Baker N, Rojewski A, Toll B. Tobacco use and cancer‐related symptom burden: Analysis of the US Population Assessment of Tobacco and Health Study. Cancer 2023, 129: 2385-2394. PMID: 37211959, PMCID: PMC10593116, DOI: 10.1002/cncr.34746.Peer-Reviewed Original ResearchConceptsSymptom burdenCurrent smokingCigarette smokingQuit attemptsTobacco useGreater fatiguePast-year quit attemptsCancer symptom burdenUS Population AssessmentCurrent cigarette smokingGreater symptom burdenTobacco treatment interventionsAdult cancer survivorsQuality of lifeSmoking quit attemptEmotional problemsRace/ethnicityCancer survivorsTobacco cessationHealth StudySmokingTreatment interventionsUS FoodMultivariate analysisSurvivors' interest
2022
Urgent Need for Novel Investigations of Treatments to Quit E-cigarettes: Findings from a Systematic Review
Palmer AM, Price SN, Foster MG, Sanford BT, Fucito LM, Toll BA. Urgent Need for Novel Investigations of Treatments to Quit E-cigarettes: Findings from a Systematic Review. Cancer Prevention Research 2022, 15: 569-580. PMID: 35816038, PMCID: PMC9444997, DOI: 10.1158/1940-6207.capr-22-0172.Peer-Reviewed Original ResearchConceptsE-cigarette cessationE-cigarettesSystematic reviewE-cigarette useSymptoms of dependenceCohort studyCigarette smokingPsychologic factorsQuit attemptsHealth concernCessationCold turkeySmokingLack of satisfactionHigher intentFuture studiesAdultsInterventionAdult samplesUrgent needLack of informationReviewSymptomsAbstinenceIndividualsOvernight Abstinence Is Associated With Smaller Secondary Somatosensory Cortical Volumes and Higher Somatosensory-Motor Cortical Functional Connectivity in Cigarette Smokers
Chen Y, Dhingra I, Chaudhary S, Fucito L, Li CR. Overnight Abstinence Is Associated With Smaller Secondary Somatosensory Cortical Volumes and Higher Somatosensory-Motor Cortical Functional Connectivity in Cigarette Smokers. Nicotine & Tobacco Research 2022, 24: 1889-1897. PMID: 35796689, PMCID: PMC9653081, DOI: 10.1093/ntr/ntac168.Peer-Reviewed Original ResearchConceptsResting-state functional connectivityGray matter volumeWithdrawal symptom severityOvernight abstinenceFunctional connectivityRight SIISymptom severityCigarette smokersSomatosensory cortexMatter volumeRight secondary somatosensory cortexSmaller gray matter volumeSubcortical gray matter volumesSecond somatosensory cortexSecondary somatosensory cortexCortical functional connectivityMotor impulsivityVoxel-wise morphometryRegional gray matter volumeLeft ventral hippocampusGMV alterationsCigarette smokingSatiety stateAbstinence symptomsHigher-order sensory corticesCigarette Smoking in Response to COVID-19: Examining Co-Morbid Medical Conditions and Risk Perceptions
Fucito LM, Bold KW, Cannon S, Serrantino A, Marrero R, O’Malley S. Cigarette Smoking in Response to COVID-19: Examining Co-Morbid Medical Conditions and Risk Perceptions. International Journal Of Environmental Research And Public Health 2022, 19: 8239. PMID: 35886090, PMCID: PMC9317071, DOI: 10.3390/ijerph19148239.Peer-Reviewed Original ResearchConceptsChronic medical conditionsMedical conditionsCigarette smokingCOVID-19 risk perceptionCOVID-19 riskGreater oddsSmoking changesHigher COVID-19 risk perceptionsCo-morbid medical conditionsCOVID-19Tobacco cessation treatmentCoronavirus disease 2019 (COVID-19) pandemicDisease 2019 pandemicPublic health threatCessation treatmentMedical historyWhite raceSmokingSmoking behaviorSample of adultsOngoing COVID-19Younger ageLogistical regressionHealth threatPreventive healthcare
2021
Cigarette Smoking and Heavy Alcohol Drinking: The Challenges and Opportunities for Combination Treatments
King A, Fucito L. Cigarette Smoking and Heavy Alcohol Drinking: The Challenges and Opportunities for Combination Treatments. American Journal Of Psychiatry 2021, 178: 783-785. PMID: 34516230, DOI: 10.1176/appi.ajp.2021.21070692.Peer-Reviewed Original ResearchThe effect of varenicline on smoking and drinking outcomes among Black and White adults with alcohol use disorder and co-occurring cigarette smoking: A secondary analysis of two clinical trials
Haeny AM, Gueorguieva R, Montgomery L, Bold KW, Fucito LM, Wu R, Muvvala SB, Zweben A, O'Malley SS. The effect of varenicline on smoking and drinking outcomes among Black and White adults with alcohol use disorder and co-occurring cigarette smoking: A secondary analysis of two clinical trials. Addictive Behaviors 2021, 122: 106970. PMID: 34216871, PMCID: PMC9426655, DOI: 10.1016/j.addbeh.2021.106970.Peer-Reviewed Original ResearchConceptsEffects of vareniclineAlcohol use disorderCigarette smokingClinical trialsUse disordersWhite adultsEfficacy of vareniclineNumber of drinksVareniclineSmokingPrimary analysisAlcohol treatmentSecondary analysisAlcohol useTrialsBlack participantsDrinking outcomesLinear mixed modelsAdultsWhite peopleWhite participantsMixed modelingCigarettesDisordersTreatment
2019
Longitudinal Findings from a Randomized Clinical Trial of Varenicline for Alcohol Use Disorder with Comorbid Cigarette Smoking
Bold KW, Zweben A, Fucito LM, Piepmeier ME, Muvvala S, Wu R, Gueorguieva R, O'Malley SS. Longitudinal Findings from a Randomized Clinical Trial of Varenicline for Alcohol Use Disorder with Comorbid Cigarette Smoking. Alcohol Clinical And Experimental Research 2019, 43: 937-944. PMID: 30817018, PMCID: PMC7039307, DOI: 10.1111/acer.13994.Peer-Reviewed Original ResearchConceptsEnd of treatmentAlcohol use disorderHeavy drinking daysMedical managementCigarette smokingComorbid cigarette smokingUse disordersDrinking daysCo-occurring alcohol use disorderHigh ratePlacebo-controlled trialBetter clinical outcomesAssessment of alcoholPercent of participantsVarenicline treatmentClinical outcomesSmoking abstinenceParallel groupClinical trialsTimeline FollowVareniclineSmoking behaviorAlcohol treatmentPosttreatment outcomesMultisite trialElectronic cigarette and tobacco use in individuals entering methadone or buprenorphine treatment
Baldassarri SR, Fiellin DA, Savage ME, Madden LM, Beitel M, Dhingra LK, Fucito L, Camenga D, Bollampally P, Barry DT. Electronic cigarette and tobacco use in individuals entering methadone or buprenorphine treatment. Drug And Alcohol Dependence 2019, 197: 37-41. PMID: 30769264, PMCID: PMC6637405, DOI: 10.1016/j.drugalcdep.2018.12.012.Peer-Reviewed Original ResearchConceptsOpioid use disorderOpioid agonist therapyCurrent cigarette smokingCigarette smokingEC useHigher oddsFormer smokersLower oddsPsychiatric distressPast cigarette smokingElectronic cigarette useAgonist therapyCurrent smokersBuprenorphine treatmentChronic painTobacco useNicotine dependenceUse disordersSmokingCigarette useMultivariate analysisElectronic cigarettesSmokersCigarettesMultivariate model
2018
Effect of Varenicline Combined With Medical Management on Alcohol Use Disorder With Comorbid Cigarette Smoking: A Randomized Clinical Trial
O’Malley S, Zweben A, Fucito LM, Wu R, Piepmeier ME, Ockert DM, Bold KW, Petrakis I, Muvvala S, Jatlow P, Gueorguieva R. Effect of Varenicline Combined With Medical Management on Alcohol Use Disorder With Comorbid Cigarette Smoking: A Randomized Clinical Trial. JAMA Psychiatry 2018, 75: 129-138. PMID: 29261824, PMCID: PMC5838706, DOI: 10.1001/jamapsychiatry.2017.3544.Peer-Reviewed Original ResearchConceptsAlcohol use disorderMedical managementUse disordersCigarette smokingWeek 9Varenicline tartrateEfficacy of vareniclinePlacebo-controlled trialBehavioral health risksComorbid cigarette smokingRace/ethnicityAlcohol dependence criteriaSmoking 2Medication adherenceOutpatient clinicPlacebo pillsMean ageEligible participantsSmoking abstinenceClinical trialsParallel groupPlaceboMAIN OUTCOMEVareniclineWeek 13
2016
Resting-State Functional Connectivity of the Basal Nucleus of Meynert in Cigarette Smokers: Dependence Level and Gender Differences
Zhang S, Hu S, Fucito LM, Luo X, Mazure CM, Zaborszky L, Li CR. Resting-State Functional Connectivity of the Basal Nucleus of Meynert in Cigarette Smokers: Dependence Level and Gender Differences. Nicotine & Tobacco Research 2016, 19: 452-459. PMID: 27613921, PMCID: PMC6074817, DOI: 10.1093/ntr/ntw209.Peer-Reviewed Original ResearchConceptsSupplementary motor areaCigarette smokersCholinergic systemCigarette smokingFemale smokersMotor areaBasal nucleusFunctional connectivityResting-state functional connectivityGender-matched nonsmokersWhole-brain functional connectivityNicotine dependence scoresBilateral anterior insulaNicotinic acetylcholine receptorsPosterior cingulate cortexCurrent smokersMale smokersCerebral cortexCholinergic projectionsMultiple imaging modalitiesBasal forebrainGreater negative connectivitySex-specific differencesSmokersFagerström Test
2014
Addressing the Evidence for FDA Nicotine Replacement Therapy Label Changes: A Policy Statement of the Association for the Treatment of Tobacco Use and Dependence and the Society for Research on Nicotine and Tobacco
Fucito LM, Bars MP, Forray A, Rojewski AM, Shiffman S, Selby P, West R, Foulds J, Toll BA, Networks W. Addressing the Evidence for FDA Nicotine Replacement Therapy Label Changes: A Policy Statement of the Association for the Treatment of Tobacco Use and Dependence and the Society for Research on Nicotine and Tobacco. Nicotine & Tobacco Research 2014, 16: 909-914. PMID: 24919399, PMCID: PMC6281057, DOI: 10.1093/ntr/ntu087.Peer-Reviewed Original ResearchConceptsQuit attemptsQuit dateSmoking reductionEffective smoking cessation interventionsSubstantial public health burdenAid smoking cessationNicotine patch useSmoking cessation interventionPublic health burdenShort-acting formsNRT formulationsNRT medicationsRecalcitrant smokersNicotine patchCessation interventionsCigarette smokingSmoking cessationHealth burdenProvider consultationTobacco useDrug AdministrationRelapse preventionSmokersLabeling changesMonths
2013
Predictors of Interest in an Alcohol Reduction Clinical Trial of Naltrexone among Undergraduates
Leeman RF, Corbin WR, Fucito LM, Urwin JW, O’Malley S. Predictors of Interest in an Alcohol Reduction Clinical Trial of Naltrexone among Undergraduates. Journal Of Addiction Research & Therapy 2013, 4: 151. PMID: 24511431, PMCID: PMC3917969, DOI: 10.4172/2155-6105.1000151.Peer-Reviewed Original ResearchClinical trialsPredictors of interestTrend-level predictorCurrent cigarette smokingNon-white raceCigarette smokingDrinking reductionsPast-year drinkersTreatment engagementHeavy drinkersReduction messagesAlcohol-related negative consequencesYoung adultsSignificant predictorsTrialsNaltrexonePredictorsRandom sampleDrinkersRegression modelsFull regression modelCounselingEquivalent levelsHigher numberMedications
2012
Cigarette Smoking Predicts Differential Benefit from Naltrexone for Alcohol Dependence
Fucito LM, Park A, Gulliver SB, Mattson ME, Gueorguieva RV, O'Malley SS. Cigarette Smoking Predicts Differential Benefit from Naltrexone for Alcohol Dependence. Biological Psychiatry 2012, 72: 832-838. PMID: 22541040, PMCID: PMC3410039, DOI: 10.1016/j.biopsych.2012.03.023.Peer-Reviewed Original ResearchConceptsCigarette smokingAlcohol dependenceBehavioral interventionsAlcohol-dependent smokersCombination of medicationsBaseline demographic differencesPoor treatment outcomesPoor treatment responseDrinking outcomesBetter drinking outcomesSevere alcohol dependenceAlcohol-dependent individualsCigarette intakeAlcohol use outcomesMedical managementPharmacological treatmentTreatment outcomesTreatment responseSmokingSmokersCOMBINE StudyAlcoholism typologyDrinking-related variablesTreatment assignmentNonsmokers
2011
A preliminary investigation of varenicline for heavy drinking smokers
Fucito LM, Toll BA, Wu R, Romano DM, Tek E, O’Malley S. A preliminary investigation of varenicline for heavy drinking smokers. Psychopharmacology 2011, 215: 655-663. PMID: 21221531, PMCID: PMC3645986, DOI: 10.1007/s00213-010-2160-9.Peer-Reviewed Original ResearchConceptsHeavy drinking smokersActive medicationPretreatment groupAlcohol cravingHeavy drinkersOpen-label phaseSmoking cessation pharmacotherapyEffects of vareniclineHeavy drinking daysGreater reductionPlacebo leadVarenicline pretreatmentCessation counselingCessation pharmacotherapyAbstinence ratesCigarette smokingVareniclineSmoking changesDrinking daysPotential treatmentSmokingAlcohol dependenceEntire study periodSmokersHeavy drinking